Insider Profile · SEC Form 4 Activity · Trailing 90 Days
Orbimed Genesis Gp Llc
Over the trailing 90 days, Orbimed Genesis Gp Llc (Director at Enliven Therapeutics, Inc.) traded $66.7M of stock (net selling $36.7M) across 3 companies, per 14 SEC Form 4 transactions.
- Role
- Director
- Window
- Trailing 90 days · 14 transactions · CIK 1808744
- Net activity
- −$36.7M ($15.0M bought · $51.7M sold)
By Company (Trailing 90 Days)
Transactions (14)
| Date | Symbol | Type | Shares | Value | Description |
|---|---|---|---|---|---|
| 2026-06-22 | ELVN | Sell | 1.5K | $66K | Open market or private sale |
| 2026-06-22 | ELVN | Sell | 24.8K | $1.1M | Open market or private sale |
| 2026-06-22 | ELVN | Sell | 46.8K | $2.1M | Open market or private sale |
| 2026-06-22 | ELVN | Sell | 787.0K | $35.7M | Open market or private sale |
| 2026-06-15 | ELVN | Sell | 9.1K | $409K | Open market or private sale |
| 2026-06-15 | ELVN | Sell | 272.3K | $12.3M | Open market or private sale |
| 2026-06-11 | STTK | Buy | 208.3K | $0 | Open market or private purchase |
| 2026-06-11 | STTK | Buy | 1.0M | $0 | Open market or private purchase |
| 2026-06-08 | STTK | Sell | 3.1M | $0 | Conversion of derivative security |
| 2026-06-08 | STTK | Sell | 15.4M | $0 | Conversion of derivative security |
| 2026-06-08 | STTK | Buy | 3.1M | $0 | Conversion of derivative security |
| 2026-06-08 | STTK | Buy | 15.4M | $0 | Conversion of derivative security |
| 2026-05-28 | QTTB | Buy | 625.0K | $5.0M | Open market or private purchase |
| 2026-05-28 | QTTB | Buy | 1.2M | $10.0M | Open market or private purchase |
Activity shown covers the trailing 90 days of SEC Form 4 filings. "Buy" and "sell" follow the SEC acquired/disposed codes and include compensation events (grants, option exercises, tax withholding) unless noted. Historical fact, not investment advice.
Follow Orbimed's next move
Real-time Form 4 alerts, insider track records, and cluster detection — matched to your watchlist.